Modafinil

Introduction Overview

Generic Name

modafinil

Brand Name

Provigil

Dosage Form

oral tablet

Drug Class

CNS stimulants

Pharmacokinetics

Absorption: Modafinil is rapidly absorbed after oral administration, with peak plasma concentrations occurring approximately 2 to 4 hours post-dose. The oral bioavailability is high, and food intake can delay the time to peak concentration but does not significantly affect the extent of absorption. Due to its favorable absorption profile, modafinil achieves effective plasma levels quickly, making it suitable for prompting wakefulness in clinical settings such as narcolepsy, obstructive sleep apnea (OSA), and shift work sleep disorder (SWS).

Distribution: Once absorbed, modafinil is moderately bound to plasma proteins, approximately 60%, which facilitates systemic distribution to target tissues, including the central nervous system (CNS). Modafinil readily crosses the blood-brain barrier, contributing to its CNS stimulant effects. Its volume of distribution is reported to be moderate, indicating sufficient tissue penetration without extensive sequestration.

Metabolism: The metabolism of modafinil occurs primarily in the liver via hepatic enzymes, especially cytochrome P450 isoenzymes CYP3A4 and CYP2C19. It is metabolized into inactive metabolites mainly through hydrolytic and oxidative pathways. Modafinil is known to induce its own metabolism upon chronic use and can induce CYP3A4 while inhibiting CYP2C19, which is clinically important for potential drug-drug interactions with substrates of these enzymes.

Elimination: Modafinil and its metabolites are primarily eliminated via the kidneys. The terminal half-life ranges from approximately 10 to 15 hours in healthy individuals, supporting once-daily dosing regimens. Excretion occurs mainly as metabolites in the urine, with less than 10% of unchanged drug detected. The clearance rate may be altered in individuals with hepatic or renal impairment, requiring careful clinical monitoring. Modafinil’s moderately long half-life contributes to sustained wakefulness-promoting effects throughout the day.

Dosage Forms

Available Dosage Forms: Modafinil is formulated exclusively as oral tablets for systemic administration. The tablets are available in the following strengths: 100 mg and 200 mg.

Dosages for Adults and Adolescents: The recommended adult dose for narcolepsy and obstructive sleep apnea/hypopnea syndrome (OSAHS) is 200 mg once daily, usually administered in the morning to align with natural wakefulness patterns. For shift work sleep disorder, modafinil is typically taken as a single dose of 200 mg approximately one hour before the start of the work shift to provide optimal alertness during working hours. Modafinil is not approved for use in individuals younger than 17 years old due to lack of safety and efficacy data and potential risks.

Specific Patient Populations: Modafinil dosing requires caution and individualized assessment in patients with hepatic impairment, renal dysfunction, or cardiovascular disease. No dosage adjustments are explicitly established for mild to moderate hepatic or renal impairment; however, patients with severe conditions should be carefully monitored. Use in pregnant or breastfeeding women is not recommended unless benefits outweigh risks. Modafinil may reduce the effectiveness of hormonal contraceptives, necessitating alternative or additional contraceptive measures during treatment and for at least one month after discontinuation.

Mechanism Of Action

Modafinil’s precise molecular mechanism of action remains incompletely understood, distinguishing it from classical CNS stimulants like amphetamines and methylphenidate. It is believed to promote wakefulness primarily through modulation of neurotransmitter systems that regulate the sleep-wake cycle.

At the neurochemical level, modafinil increases extracellular concentrations of monoamines such as dopamine and norepinephrine by inhibiting their reuptake through transporter sites in key brain regions involved in arousal including the hypothalamus and thalamus. This modulation leads to enhanced neuronal firing and alertness.

In addition, modafinil appears to influence other neurotransmitters and neuropeptides, such as orexin/hypocretin, gamma-aminobutyric acid (GABA), and glutamate, contributing to its wake-promoting effects. It elevates hypothalamic histamine levels, further stimulating arousal pathways without the marked euphoric effects associated with traditional stimulants.

Clinically, modafinil’s unique pharmacological profile results in a milder stimulant effect with a lower potential for abuse and dependence compared to amphetamines. Modafinil facilitates cognitive functions such as attention and executive function by enhancing cortical activation, making it beneficial in conditions characterized by excessive sleepiness without inducing significant sympathomimetic side effects. Comparative studies reflect its safe and effective profile in promoting daytime wakefulness while minimizing cardiovascular risks seen with more potent stimulants.

Pharmacological Actions

Promotes wakefulness and alertness by modulating central nervous system pathways.
Inhibits dopamine reuptake through dopamine transporter blockade, increasing extracellular dopamine levels.
Enhances release of norepinephrine and possibly serotonin, contributing to stimulant effects.
Augments hypothalamic histamine release, supporting sustained cortical activation and arousal.
Influences orexin/hypocretin system, a key regulator of arousal and sleep-wake states.
Increases glutamate release while decreasing GABAergic inhibitory signaling to maintain wakefulness.
Exerts stimulant-like effects without typical sympathomimetic side effects such as tachycardia.
Minimal euphoric effects, resulting in reduced abuse potential relative to traditional amphetamines.
Improves cognitive domains including attention, executive function, and memory in both sleep-deprived and non-sleep-deprived individuals.
May induce hepatic cytochrome P450 enzymes affecting metabolism of other drugs.
Demonstrates neuroprotective effects in some preclinical models by reducing oxidative stress.
Does not significantly increase dopamine release in the nucleus accumbens, explaining its lower addiction potential.
Promotes prolonged wakefulness without disrupting the overall architecture of normal sleep during off-treatment periods.
Modulates multiple neurotransmitter systems in a balanced manner to reduce excessive daytime sleepiness.

Therapeutic Or Clinical Uses

Treatment of excessive daytime sleepiness associated with narcolepsy.
Management of excessive sleepiness in obstructive sleep apnea/hypopnea syndrome (OSAHS) adjunctive to primary treatments such as CPAP.
Treatment of shift work sleep disorder (SWS) to improve wakefulness during abnormal work hours.
Off-label use for cognitive enhancement in disorders with fatigue or cognitive dysfunction (requires clinical discretion).
Potential investigational use in depression-related fatigue and multiple sclerosis fatigue.
Adjunct therapy in conditions with hypersomnolence refractory to standard treatments.
Reduction of excessive sleepiness in Parkinson’s disease and other neurodegenerative disorders (off-label).
Controlled use to mitigate sedation effects of certain medications in clinical practice.
Investigated for use in attention-deficit hyperactivity disorder (ADHD), though not FDA-approved for pediatric populations.
Supportive treatment for fatigue in chronic fatigue syndrome in selected clinical scenarios.
Management of cognitive impairment and fatigue in cancer-related conditions (under research).
Used to improve wakefulness in patients with shift work-induced circadian rhythm disturbances.
Sometimes prescribed off-label for treatment-resistant depression to augment antidepressants.
Considered as part of treatment regimens to improve quality of life in selected patients with sleep-related disorders.
Helpful for individuals with excessive daytime somnolence impairing social and occupational functioning.

Side Or Adverse Effects

Headache, the most commonly reported adverse effect.
Dizziness and lightheadedness during initial treatment phases.
Nervousness, anxiety, and agitation reflecting CNS stimulation.
Insomnia or difficulty falling and staying asleep due to wake-promoting mechanisms.
Gastrointestinal symptoms including nausea, diarrhea, and upset stomach.
Decreased appetite potentially leading to weight loss in some patients.
Back pain and muscle aches noted in certain individuals.
Stuffy or runny nose as a minor but frequently reported complaint.
Rare but serious skin reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and severe rash with blistering or peeling.
Hypersensitivity reactions including angioedema and anaphylaxis warranting immediate discontinuation.
Psychiatric symptoms including anxiety, confusion, hallucinations, depression, agitation, and suicidal ideation.
Cardiovascular effects such as chest pain, palpitations, arrhythmias, and hypertension in susceptible patients.
Potential for dependence and misuse, although lower than traditional CNS stimulants.
Increased liver enzymes or hepatic impairment in rare cases.
Potential for reduced efficacy or interference when combined with other CNS-active agents.

Precautions

Use cautiously in patients with a history of cardiovascular disease including angina and arrhythmias.
Assess liver and renal function before and during prolonged therapy due to hepatic metabolism and renal elimination.
Avoid use in individuals with a history of hypersensitivity to modafinil, armodafinil, or related compounds.
Careful psychiatric evaluation is recommended as modafinil may exacerbate existing mental health disorders or cause new psychiatric symptoms.
Advise patients on the risk of impaired judgment, slower reaction times, and alertness despite perceived wakefulness when driving or operating machinery.
Monitor closely in patients with history of substance abuse due to potential for dependency.
Use caution in pregnant women as modafinil may harm the fetus; alternative treatments should be considered.
Inform women of childbearing potential about decreased efficacy of hormonal contraceptives and recommend additional contraceptive methods.
Avoid abrupt discontinuation to prevent potential withdrawal symptoms.
Careful consideration advised in patients with severe hypertension or uncontrolled high blood pressure.
Avoid combining with monoamine oxidase inhibitors (MAOIs) without medical supervision due to interaction risks.
Use with caution in elderly patients due to increased sensitivity to adverse effects.
Monitor for dermatologic reactions vigilantly; discontinue immediately if severe rash or mucosal lesions appear.
Advise against alcohol consumption during treatment to reduce risk of CNS adverse effects.
Ensure adherence to prescribed dosing and discourage sharing or misuse due to controlled substance status.

Warnings

Risk of severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis necessitates immediate drug discontinuation if rash develops.
Potential for serious hypersensitivity reactions such as angioedema and anaphylaxis.
May cause psychiatric adverse events such as depression, suicidal ideation, hallucinations, and aggression requiring prompt medical assessment.
Possible cardiovascular complications including chest pain, palpitations, and arrhythmias; discontinue if such symptoms occur.
Impairment of thinking and alertness despite subjective wakefulness; caution advised when performing hazardous tasks.
Not a substitute for adequate sleep or primary therapies for underlying sleep disorders.
Risk of decreased efficacy of hormonal contraception leading to unintended pregnancy; additional contraceptive measures are required.
Schedule IV controlled substance due to potential for abuse and dependence.
Avoid use in pediatric patients under 17 years due to safety concerns and lack of FDA approval.
Risk of overdose with symptoms such as agitation, tachycardia, hypertension, and hallucinations requiring emergency care.
Long-term safety beyond 12 weeks has not been established; ongoing evaluation needed.
Use with caution in patients with a history of substance misuse, psychiatric illness, or cardiovascular disease.
Be alert for signs of angina or cardiac ischemia in predisposed individuals.
Potential interactions with other medications that may exacerbate side effects or reduce therapeutic efficacy.
Discontinue immediately if signs of hypersensitivity or severe side effects develop.

Contraindication

Known hypersensitivity or allergic reaction to modafinil, armodafinil, Provigil, or any formulation components.
History of severe rash or hypersensitivity reactions to modafinil or related agents.
Concomitant use with monoamine oxidase inhibitors (MAOIs) within 14 days due to risk of serious interactions.
Patients under 17 years of age due to increased risk of serious adverse effects and lack of approved indication.
Use in pregnancy unless potential benefit justifies potential risk to the fetus.
Severe hepatic impairment where metabolism and clearance are significantly compromised.
Concomitant use with other potent CNS stimulants without medical supervision.
Known history of drug or alcohol abuse without proper medical oversight.
Uncontrolled hypertension or unstable cardiovascular disease may be a relative contraindication.
Severe renal impairment lacking appropriate dosing adjustments.
Patients with known hypersensitivity to pill excipients such as lactose (for those with lactose intolerance).
Use during breastfeeding is contraindicated or should be avoided unless necessary.
Situations where increased wakefulness might be detrimental such as during recovery from major surgery or illness.
Patients with psychotic disorders unless clinically justified and monitored intensively.
Individuals with hypersensitivity to any CNS stimulants may require avoidance.

Drug Interactions

Modafinil induces cytochrome P450 enzyme CYP3A4, which can decrease the plasma concentrations of drugs metabolized by this pathway, including some hormonal contraceptives, cyclosporine, midazolam, and triazolam.
Modafinil inhibits CYP2C19, potentially increasing plasma levels and effects of medications like phenytoin, diazepam, propranolol, omeprazole, and clomipramine, increasing risk of side effects or toxicity.
Co-administration with warfarin may alter prothrombin times/international normalized ratio (INR), necessitating close monitoring of anticoagulation parameters.
May interact adversely with monoamine oxidase inhibitors (MAOIs), raising the risk of hypertensive crises or serotonin syndrome.
Potential to reduce efficacy of hormonal contraceptives, leading to increased risk of unintended pregnancy.
Concurrent use with other CNS stimulants may potentiate adverse cardiovascular and neuropsychiatric effects.
Interaction with sedative-hypnotics may reduce their efficacy due to enhancing wakefulness.
May affect metabolism of anticonvulsants via cytochrome P450 modulation, affecting seizure control.
Possible interactions with certain antidepressants, requiring monitoring for increased side effects or reduced efficacy.
Concomitant use with alcohol increases risk of CNS adverse effects like dizziness and impaired judgment.
Drugs that inhibit CYP3A4 (e.g., ketoconazole) can increase modafinil plasma levels, potentially augmenting side effects.
Inducers of CYP3A4 (e.g. carbamazepine) may reduce modafinil levels, diminishing its therapeutic effects.
Use caution with beta-blockers like propranolol as modafinil may increase their plasma concentrations.
Potential for pharmacodynamic interactions with antihypertensives, possibly reducing their efficacy.
Interactions with immunosuppressants, such as cyclosporine, requiring dose adjustments and monitoring.

Preparations Of The Drug

Modafinil 100 mg oral tablets manufactured by multiple generic pharmaceutical companies such as Alembic Pharmaceuticals Inc., Apotex Corp., and Aurobinda Pharma Ltd.
Modafinil 200 mg oral tablets marketed under the brand name Provigil by Cephalon, LLC.
Inactive ingredients in Provigil tablets include croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and pregelatinized starch to ensure tablet stability and bioavailability.
Generic modafinil products may vary slightly in formulation excipients but contain the same active pharmaceutical ingredient.
Available only in oral solid dosage form; no injectable, topical, or extended-release formulations are commercially approved.
Packaged typically in blister packs or bottles, stored at room temperature away from moisture and heat.
Standard packaging includes bottles containing 30, 60, or 90 tablets depending on manufacturer and prescription.
Prescribed primarily as a prescription-only medication due to its status as a Schedule IV controlled substance.
Available globally with regulatory approvals for indications related to excessive daytime sleepiness and shift work sleep disorder.
No combination formulations are commercially available; modafinil is administered as monotherapy.
Patient information leaflets are provided with each packaging, containing detailed dosing instructions and safety information.
Manufacturers provide risk management and abuse deterrence information in the medication guides.
Specialty pharmacy services may be required for distribution in certain healthcare systems.
Generic formulations meet stringent bioequivalence criteria to the branded Provigil tablets.
Modafinil tablets are film-coated to improve swallowing and mask the bitter taste of the active compound.